Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Electra Therapeutics | 2025 | Series C | $183.0M | San Francisco |
| Spyre Therapeutics | 2025 | Post Ipo Equity | $275.0M | Sunrise |
| Biomea Fusion | 2025 | Post Ipo Equity | $25.0M | Redwood City |
| Averto Medical | 2025 | Grant | $2.1M | Belmont |
| Star Therapeutics | 2025 | Undisclosed | $125.0M | South San Francisco |
| Ensoma | 2025 | Series Unknown | $53.0M | Boston |
| Oruka Therapeutics | 2025 | Post Ipo Equity | $180.0M | Waltham |
| Tioga Cardiovascular | 2025 | Series D | $22.9M | Campbell |
| Avidity Biosciences | 2025 | Post Ipo Equity | $690.0M | San Diego |
| Rapport Therapeutics | 2025 | Post Ipo Equity | $250.0M | Boston |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 51 | Electra Therapeutics | Series C | $183.0M | San Francisco, United States |
| 52 | Spyre Therapeutics | Post Ipo Equity | $275.0M | Sunrise, United States |
| 53 | Biomea Fusion | Post Ipo Equity | $25.0M | Redwood City, United States |
| 54 | Averto Medical | Grant | $2.1M | Belmont, United States |
| 55 | Star Therapeutics | Undisclosed | $125.0M | South San Francisco, United States |
| 56 | Ensoma | Series Unknown | $53.0M | Boston, United States |
| 57 | Oruka Therapeutics | Post Ipo Equity | $180.0M | Waltham, United States |
| 58 | Tioga Cardiovascular | Series D | $22.9M | Campbell, United States |
| 59 | Avidity Biosciences | Post Ipo Equity | $690.0M | San Diego, United States |
| 60 | Rapport Therapeutics | Post Ipo Equity | $250.0M | Boston, United States |
Electra Therapeutics is a clinical-stage biotechnology company developing antibody therapies for immunological diseases and cancer.
Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.
Biomea Fusion is a precision oncology company developing novel small molecules that target aggressive forms of cancer.
Averto Medical is a medical device manufacturing company.
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.
Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.
Tioga Cardiovascular is a healthcare company providing valve replacement solutions for mitral and tricuspid applications.
Synapse Energy Economics is a consulting firm providing economic and policy analysis for the electric power sector.
Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.
AccurEdit develops safe, targeted in vivo gene editing and delivery tech for severe hereditary and acquired diseases.
BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3Kα malignancies.
Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.
Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.
Attovia Therapeutics is a biologics platform specializing in biotherapeutics for immune-mediated diseases.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions.
Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain.
Stratus Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Cormorant Asset Management has invested in 134 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 15 different industry categories.
Among tracked funding rounds, Avidity Biosciences received $690.0M in a Post Ipo Equity round. Cormorant Asset Management's total known invested capital is $11.5B.
Cormorant Asset Management's average investment size is $127.4M across its portfolio of 134 companies.
Recent Cormorant Asset Management portfolio additions include Electra Therapeutics, Spyre Therapeutics, Biomea Fusion, Averto Medical, Star Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors